Is Akebia Therapeutics Incorporated (NASDAQ:AKBA) a Buy? The Stock Reported Less Sellers

November 14, 2017 - By Clifton Ray

 Is Akebia Therapeutics Incorporated (NASDAQ:AKBA) a Buy? The Stock Reported Less Sellers

Investors sentiment increased to 2.25 in 2017 Q2. Its up 1.17, from 1.08 in 2017Q1. It is positive, as 10 investors sold Akebia Therapeutics Inc shares while 22 reduced holdings. 38 funds opened positions while 34 raised stakes. 26.05 million shares or 30.12% more from 20.02 million shares in 2017Q1 were reported.
Federated Investors Pa accumulated 244 shares or 0% of the stock. 20,478 were accumulated by D E Shaw &. Landscape Management Limited Liability Co has invested 0.04% in Akebia Therapeutics Inc (NASDAQ:AKBA). First Manhattan accumulated 1.19 million shares. Jane Street Gru Incorporated Limited Liability Com holds 26,186 shares. Spark Management Lc holds 0.03% or 31,800 shares in its portfolio. Manufacturers Life Ins The has 0% invested in Akebia Therapeutics Inc (NASDAQ:AKBA) for 29,728 shares. Moreover, Millennium Mgmt Ltd Co has 0.02% invested in Akebia Therapeutics Inc (NASDAQ:AKBA) for 586,914 shares. Numeric Llc holds 0.08% of its portfolio in Akebia Therapeutics Inc (NASDAQ:AKBA) for 621,967 shares. Proshare Advsrs Limited Liability Corporation holds 0% of its portfolio in Akebia Therapeutics Inc (NASDAQ:AKBA) for 23,208 shares. Piermont Cap Management holds 55,075 shares. 10,921 are owned by Guggenheim Limited Liability Corporation. Ra Ltd Co stated it has 836,337 shares. Tudor Corp Et Al stated it has 12,155 shares or 0.01% of all its holdings. Marshall Wace Ltd Liability Partnership holds 0.06% or 97,294 shares in its portfolio.

The stock of Akebia Therapeutics Incorporated (NASDAQ:AKBA) registered a decrease of 14.17% in short interest. AKBA’s total short interest was 2.27M shares in November as published by FINRA. Its down 14.17% from 2.64M shares, reported previously. With 298,200 shares average volume, it will take short sellers 8 days to cover their AKBA’s short positions. The short interest to Akebia Therapeutics Incorporated’s float is 15.62%.

About 45,092 shares traded. Akebia Therapeutics Inc (NASDAQ:AKBA) has risen 76.80% since November 14, 2016 and is uptrending. It has outperformed by 60.10% the S&P500.

Akebia Therapeutics, Inc. is a biopharmaceutical company. The company has market cap of $683.98 million. The Firm focuses on the development and commercialization of therapeutics based on hypoxia-inducible factor biology. It currently has negative earnings. The Company’s lead product candidate, vadadustat, is indicated for the treatment of anemia in chronic kidney disease (CKD).

Akebia Therapeutics Inc (NASDAQ:AKBA) Ratings Coverage

Among 9 analysts covering Akebia Therapeutics Inc (NASDAQ:AKBA), 7 have Buy rating, 0 Sell and 2 Hold. Therefore 78% are positive. Akebia Therapeutics Inc had 22 analyst reports since August 13, 2015 according to SRatingsIntel. H.C. Wainwright maintained Akebia Therapeutics Inc (NASDAQ:AKBA) rating on Tuesday, December 15. H.C. Wainwright has “Buy” rating and $25.0 target. The firm earned “Buy” rating on Thursday, August 13 by Brean Capital. Brean Capital maintained Akebia Therapeutics Inc (NASDAQ:AKBA) on Wednesday, September 9 with “Buy” rating. The rating was upgraded by Morgan Stanley on Wednesday, September 9 to “Overweight”. As per Monday, June 5, the company rating was maintained by Aegis Capital. H.C. Wainwright maintained the shares of AKBA in report on Tuesday, March 15 with “Buy” rating. Credit Suisse initiated the stock with “Neutral” rating in Thursday, January 21 report. The stock has “Buy” rating by Mizuho on Wednesday, October 4. The firm earned “Buy” rating on Tuesday, December 27 by H.C. Wainwright. The firm has “Buy” rating by Aegis Capital given on Tuesday, November 15.

More notable recent Akebia Therapeutics Inc (NASDAQ:AKBA) news were published by: which released: “Akebia Therapeutics Forges Deals To Manage Costs And Profitability” on June 05, 2017, also with their article: “Revisiting Akebia Therapeutics” published on July 05, 2017, published: “Akebia Therapeutics Is A Buy With The Recent Stock Price Pullback” on November 10, 2017. More interesting news about Akebia Therapeutics Inc (NASDAQ:AKBA) were released by: and their article: “Why Akebia Therapeutics Stock Is Skyrocketing Today” published on May 16, 2017 as well as‘s news article titled: “Akebia Therapeutics Breaking Out?” with publication date: May 23, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.